Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | IL6 | P05231 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713305 | 0.83 | ADRB2 (0.39) | ADRB2LOXL2ALDH1A1TP53POLB | |
| SCHEMBL1713357 | 0.78 | CACNA1B (0.39) | ADRB2LOXL2TP53MAPTCACNA1B | |
| SCHEMBL1713662 | 0.78 | ACACB (0.45) | ADRB2LOXL2ALDH1A1TP53POLB | |
| SCHEMBL1713168 | 0.77 | TAAR1 (0.49) | — | |
| SCHEMBL12967309 | 0.76 | L3MBTL1 (0.42) | ALDH1A1TDP1KDM4EMMP13 | |
| Hydrochloric Acid SCHEMBL1713702 | 0.76 | KDM4E (0.36) | ADRB2LOXL2TP53POLBKDM4E | |
| SCHEMBL1108585 | 0.73 | KDM4E (0.61) | ALDH1A1POLBKDM4ECYP3A4MAPT | |
| SCHEMBL26761783 | 0.73 | MAPK14 (0.51) | LOXL2ALDH1A1POLBTDP1KDM4E | |
| SCHEMBL1713688 | 0.72 | KDM4E (0.50) | ALDH1A1POLBKDM4EMAPTLMNA | |
| SCHEMBL24733025 | 0.72 | ST14 (0.61) | LOXL2ALDH1A1KDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232101-A1 | Novel Compounds | CHAPMAN DAVID (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8183251-B2 | 1-[(4S)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]-N-methyl-N-{[4-(pyrimidin-5-yloxy)phenyl]methyl}methanesulfonamide; matrix metalloproteinase inhibitors; obstructive airways disease is asthma or chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2012-05-22 | — | — | US | disclosed |
| EP-2097406-B1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2097406-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | Astra Zeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080221139-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008065393-A1 | HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221139-A1 | Novel Compounds | MMP9, MMP2, MMP1 | ADRB2 1085/4885LOXL2 756/4885ALDH1A1 282/4885 |
| US-20120232101-A1 | Novel Compounds | MMP9, MMP2, MMP1 | ADRB2 1085/4885LOXL2 756/4885ALDH1A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.